SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR

SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR

This invention relates to sustained release dosage forms comprising {f-1-[3 fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-y1-3- [4-(7H-pyrrolo[2,3 d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: YELESWARAM, Krishnaswamy, PARIKH, Bhavnish, MODI, Dilip P, SHETH, Trupti
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This invention relates to sustained release dosage forms comprising {f-1-[3 fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-y1-3- [4-(7H-pyrrolo[2,3 d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto. FIG. 4(a) m o-2 0 20 40 60 80 Day -0- Placebo -a- 100 mgBID -+-200 mgBID -0- 300 mg QD -- 600 mg QD FIG. 4(b) 4- 13 (0 0 E + w -2 0I + o 500 1000 150 Cavg (nM) o Placebo A 100mgBID + 200 mg BID o 300 mg QD a 600 mg QD